M
Michal Lotem
Researcher at Hebrew University of Jerusalem
Publications - 137
Citations - 14389
Michal Lotem is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Melanoma & Immunotherapy. The author has an hindex of 28, co-authored 115 publications receiving 11780 citations. Previous affiliations of Michal Lotem include University of Sydney & Hadassah Medical Center.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert,Caroline Robert,Caroline Robert,Jacob Schachter,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Omid Hamid,Christine Mateus,Christine Mateus,Ronnie Shapira-Frommer,Ronnie Shapira-Frommer,Michele Kosh,Honghong Zhou,Nageatte Ibrahim,Scot Ebbinghaus,Antoni Ribas +26 more
TL;DR: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.
Journal ArticleDOI
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
TL;DR: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Journal ArticleDOI
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter,Antoni Ribas,Georgina V. Long,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Honghong Zhou,Scot Ebbinghaus,Nageatte Ibrahim,Caroline Robert +19 more
TL;DR: The final protocol-specified survival analysis as mentioned in this paper showed that pembrolizumab continued to provide superior overall survival versus ipilimumab, with no difference between the two dosing schedules.
Journal ArticleDOI
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert,Antoni Ribas,Jacob Schachter,Ana Arance,Jean-Jacques Grob,Laurent Mortier,Adil Daud,Matteo S. Carlino,Catriona M. McNeil,Michal Lotem,James Larkin,Paul Lorigan,Bart Neyns,Christian U. Blank,Teresa M. Petrella,Omid Hamid,Shu Chih Su,Clemens Krepler,Nageatte Ibrahim,Georgina V. Long +19 more
TL;DR: Pembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting, however, the optimal duration of anti-PD-1 administration is unknown.
Journal ArticleDOI
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Olga Lyass,Beatrice Uziely,Rami Ben-Yosef,Dinah Tzemach,Norman I. Heshing,Michal Lotem,George Brufman,Alberto Gabizon +7 more
TL;DR: Doxil (ALZA Corp., Mountain View, CA) is a formulation of doxorubicin in polyethylene‐glycol coated liposomes with a prolonged circulation time and unique toxicity profile.